Crossref
Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain
JAMA · 03.11.2026 · 336 (17) · 1493
DOI: 10.1001/jama.2026.20514 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 03.11.2026. Verfasst von Rita Rubin. Beteiligte Einrichtung: Lead Senior Staff Writer, Medical News, JAMA.
Abstract (Originalsprache)
This Medical News article discusses the reasons behind the burgeoning black market for 2 unapproved GLP-1 weight loss drugs and the potential risks associated with their use.
Autor:innen und Institutionen
- Lead Senior Staff Writer, Medical News, JAMA.
Zitieren
APA
Rubin, R. (2026). Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain. JAMA, 336(17), 1493. https://doi.org/10.1001/jama.2026.20514
Vancouver
Rubin R. Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain. JAMA. 2026;336(17):1493. doi:10.1001/jama.2026.20514
BibTeX
@article{Rubin2026,
author = {Rubin, Rita},
title = {Unapproved GLP-1 Drugs Retatrutide and Zenagamtide Sold Online Are No Bargain},
journal = {JAMA},
year = {2026},
volume = {336},
number = {17},
pages = {1493},
doi = {10.1001/jama.2026.20514}
}
EUVIMED